Investigation of the neuroprotective effect of Butein against scopolamine-induced Alzheimer’s like symptoms in rats

Abstract

Objectives: Neuroprotective effect of Butein towards Scopolamine (SCO) induced Alzheimer’s disease (AD), experimental rat models. Oral dosage of SCO increases the deposition of Aβ and cognitive dysfunctions. Butein is an abundantly phytochemical constituent of Dalbergia odorifera, Caragana jubata, and Rhus verniciflua stokes has numerous biological activities such as neuroprotective, antioxidant, and anti-inflammatory properties.
Materials and methods: To conduct the study, the Wistar rat received Scopolamine (1 mg/kg) through the oral route on an alternative day for 14 days. Rats were treated at 3 different doses of Butein (25, 50, and 100 mg/kg, orally) and donepezil (5 mg/kg, orally) for fourteen days. Every week, the behavioural impairments were assessed. Afterwards, rats were sacrificed for biochemical analysis (MDA, Nitrite, and GSH).
Results: Our result indicated that Butein reduced SCO, causing cognitive impairment and biochemical and neurobehavioral changes. Butein enhanced neuroprotective impact on cognitive impairment may be owing to its antioxidant and anti-inflammatory, according to the findings.
Conclusion: Together these findings suggest that Butein's antioxidant and anti-inflammatory properties may have contributed to its neuroprotective effect, making it a promising therapeutic candidate for the treatment of cognitive impairment and AD-like symptoms.